Highlights

  • The CORIS regulatory position is the fact most worth getting right, because it has moved twice.
  • A second 510(k) submission has since been lodged to widen the indications further.
  • A US controlled market release will follow once the company has banked operational experience from those sites.
  • Nanosonics launched trophon3 partway through the first half of FY26 and released trophon2 Plus software so existing trophon2 units can access several of the newer features.

Nanosonics has confirmed it will hand down FY26 full-year results on 25 August 2026, with an investor call and webcast led by chief executive Michael Kavanagh and the chief financial officer the same day.

Two questions sit over the print. The first is whether the trophon ultrasound probe disinfection Franchise finishes the year inside the Revenue guidance range set in February.

Company Overview

Nanosonics is a Sydney-based medical device company built around a single durable idea: automating high-level disinfection of instruments that are difficult to clean by hand. Its established product, trophon, disinfects ultrasound probes using a hydrogen peroxide mist and sells on a razor-and-blade basis.

Recent Developments

The CORIS regulatory position is the fact most worth getting right, because it has moved twice. The US Food and Drug Administration granted CORIS a De Novo clearance in March 2025, but that authorisation was narrow: it covered a single Olympus video colonoscope, the Evis Exera III.

A second 510(k) submission has since been lodged to widen the indications further. Nanosonics has not published an expected decision date, and no clearance for that second filing had been announced as at 11 August 2026.

Financial Snapshot

The half-year to 31 December 2025 gave the market its most recent verified picture. Revenue was AUD 102.2 million, up 9 % (8 % in constant currency), with Recurring Revenue of AUD 75.7 million, also up 9 %. Consumables rose 9 % and service and repairs 24 %, while spare parts fell 23 %.

Gross Margin improved about two percentage points to 76.3 %. EBIT was AUD 8.4 million, up 3 % as reported and 15 % in constant currency, profit before tax was AUD 10.6 million, and the Balance Sheet carried AUD 159.8 million in cash with no Debt .

What to Watch

The immediate date is 25 August 2026, when FY26 results land alongside, in all likelihood, FY27 guidance and an update on CORIS controlled market release sites. Beyond that, the milestones to track are an FDA determination on the second 510(k) filing, the start of a US controlled market release, and the phased commercial launch guided from FY27.

Risks

CORIS revenue depends on regulatory decisions Nanosonics does not control, and the deliberate pace of the controlled market release means slippage pushes revenue further right. The trophon Business remains concentrated in North America and exposed to hospital Capital budgets; the first half showed large upgrade deals come with pricing concessions.

Outlook

The August print is a checkpoint on two clocks running at different speeds. Trophon has to land inside guidance and show the upgrade cycle converting to trophon3; CORIS has to show early hospital deployments behaving as designed and a regulatory pathway still widening.